Value-based contracting helps hold Big Pharma accountable. If the drug shows a lack of clinical effectiveness and/or results in unreported side effects, the manufacture owes the plan sponsor two-thirds of the drug’s cost. Rishi Manchanda, the Chief Medical Officer (CMO) of The Wonderful Company, believes that the sequel to the triple aim is the quadruple […]
Biosimilar drugs are identical copies of a product that has an expired patent. They are expected to increase competition and reduce drug prices. Europe, Canada, Japan, and Australia have sold dozens of biosimilar drugs for ten years. In the US, prices are expected to drop by 35%. In addition, $80 billion in sales will lose […]
Big Pharma is a dynamic and complex industry. Just a few of the stakeholders include researchers, drug companies, pharmacies, governmental agencies, health plans, doctors, and patients. Agencies such as the Food and Drug Administration (FDA), National Institutes of Health (NIH), Department of Health, and the Drug Enforcement Agency (DEA) have much influence on the pharmaceutical […]
Views on antibiotics have changed over the years. It used to be that the standard was to have doctors prescribe antibiotics for the littlest ailments. Now, doctors are to be more cautious when prescribing antibiotics and only prescribe them if it’s absolutely necessary. For antibiotics, it’s beneficial for pharmaceutical companies to limit the drug’s effectiveness […]